Open an account

Kazia Therapeutics

KZIA · NASDAQ

$7.81−$0.26 (−3.22%)TodayMarket closed ·
Prev close $8.07

About KZIA

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Employees
0
Headquarters
Sydney, New South Wales
Listed
Sep 1, 1994
Sector
Health Care
Industry
Biotechnology
Website
kaziatherapeutics.com

KZIA key statistics

Market cap
92.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
242.32K
Volume
52.68K
Open price
$7.94
High today
$8.06
Low today
$7.48
52 Week high
$17.40
52 Week low
$4.86

Kazia Therapeutics (KZIA) at a glance

Kazia Therapeutics (KZIA) last traded at $7.81, with a market cap of 92.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.48 and $8.06. The current price is 4.5% above the day's low and 3.1% below its high.

Volume so far is 52.68K shares, below the average of 242.32K shares a day.

Over the past year Kazia Therapeutics has ranged from $4.86 to $17.40, and now sits 24% of the way up that range.

Kazia Therapeutics met or beat analyst EPS estimates in 2 of the last 6 quarters. In Q2 FY26 it reported -$0.805 per share against an estimate of -$0.3315.

KZIA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 6 quarters, by 207.1% on average.

  1. Q2 FY21: reported -$29.50 per share against an estimate of -$3.06
  2. Q4 FY22: reported -$43.55 per share against an estimate of -$5.10
  3. Q4 FY23: reported -$9.50 per share against an estimate of -$2.55
  4. Q2 FY25: reported $1.42 per share against an estimate of -$1.33
  5. Q4 FY25: reported $1.42 per share against an estimate of -$1.33
  6. Q2 FY26: reported -$0.805 per share against an estimate of -$0.3315

KZIA news

  • Press releasePRNewswire

    Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

  • Press releasePRNewswire

    Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

  • Press releasePRNewswire

    Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

  • Press releasePRNewswire

    Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

  • Press releasePRNewswire

    Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

  • Press releasePRNewswire

    Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

  • Press releasePRNewswire

    Kazia Therapeutics Limited Announces Proposed Public Offering

  • Press releasePRNewswire

    Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.